Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANXA2 DARPin
- Development stage
- Preclinical
- Lead developer
- MedImmune
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ANXA2 DARPin is a designed ankyrin-repeat protein (DARPin) therapeutic candidate that targets Annexin A2 (ANXA2), a protein found to be highly expressed on the surface of pancreatic cancer stem cells (CSCs). Developed by MedImmune (a subsidiary of AstraZeneca), the drug was identified through a phenotypic selection campaign using a DARPin library. Mechanistically, the ANXA2 DARPin binds to cell-surface ANXA2, leading to a reduction in the frequency of CSCs and inhibiting tumor growth. It also decreases the secretion of pro-tumorigenic cytokines IL-6 and IL-8 and reduces plasmin activation, a pathway linked to the dissemination of cancer cells.
- Other names
- Annexin A2 DARPin
02
Targets
ANXA2 (Annexin A2)
Beyond the preview
Go deeper on ANXA2 DARPin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANXA2 DARPin.